Page 8 - Polypid Ltd News Today

03.01.2022 - Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on ... Seite 1

In this article, we discuss the 10 micro-cap stocks to buy according to Cathie Wood.

PolyPid Ltd (NASDAQ: PYPD) has received written responses from the FDA to a Type B meeting request that the company submitted regarding its ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) ...

Surgical Site Infection Market Size to Grow Remarkably with a CAGR of 22.84% for the Study Period (2018-2030), Predicts DelveInsight due to the launch of emerging therapies and increased surgical interventions due to several causes LAS VEGAS, April 28, 2021 /PRNewswire/ -- DelveInsights " Surgical Site Infection Market" report provides a thorough comprehension of the Surgical Site Infection, historical and forecasted epidemiology, and the Surgical Site Infection market trends in the 7MM [the U...

The FDA approved an expansion in the label for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SAs (NASDAQ: SNY) immunotherapy Libtayo for treating patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor, HHI, or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC. Moderna Strikes Vaccine Supply Agreements With Taiwan and Colum...

IPO Lockup Expiration Alert: PolyPid (PYPD) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23. PolyPid is a clinical-stage biopharmaceutical company developing prolonged-release therapeutics for surgical site infections using its proprietary PLEX technology. The companys lead product candidate D-PLEX??? is currently in a phase III trial for the prevention of surgical site infections (SSIs) in abdominal surgery, dubbed SHIELD I. The t...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of ... PolyPid Ltd.December 16, 2020 GMT Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical compa...